Mutations associated with a 17-gene leukemia stem cell score and its prognostic relevance in the context of the European LeukemiaNet classification for acute myeloid leukemia.
Leukemia stem cells are more resistant to standard chemotherapy and their persistence during remission can cause relapse which is still one of the major clinical challenges in the treatment of acute myeloid leukemia. A better understanding of the mutational patterns and the prognostic impact of molecular markers associated with stemness could lead to better clinical management and improve patients' outcomes. We generated a previously described 17-gene expression score comprising genes differently expressed between leukemia stem cells and leukemic bulk blasts, for 934 adult patients with de novo acute myeloid leukemia, and studied associations of the 17-gene leukemia stem cell score with clinical data and mutation status of 81 genes recurrently mutated in cancer and leukemia. We found that patients with a high 17-gene score were older and had more mutations. The 17-gene score was found to have a prognostic impact in both younger (aged <60 years) and older (aged ≥60 years) patients with acute myeloid leukemia. We also analyzed the 17-gene leukemia stem cell score in the context of the 2017 European LeukemiaNet genetic-risk classification and found that for younger patients the score further refined the classification and identified for example patient subsets with worse outcomes that are currently classified as European LeukemiaNet Favorable-risk.